What can we learn from the immune response to human factor VIIi in a mouse model of hemophilia A?
Reipert, B.M.; Schwarz, H.P.
Thrombosis and Haemostasis 88(2): 374-375
2002
ISSN/ISBN: 0340-6245 PMID: 12195723 Document Number: 549285
Document emailed within 1 workday
Related Documents
Davis, H.M.; Brown, S.K.; Nash, D.W.; Pennetti, A.M.; Salzman, P.M.; Schreiber, A.B.; Haimovich, J. 1990: Lack of immune response to mouse IgG in hemophilia a patients treated chronically with Monoclate, a monoclonal antibody affinity purified factor VIIi preparation Thrombosis and Haemostasis 63(3): 386-391Hoyer, L.W.; Qian, J. 2000: Characterization of the immune response to factor VIIi using hemophilia A* mice Haematologica 85(10 Suppl): 100-102
Ewing, N.P. 1990: Induction of immune tolerance with factor VIIi concentrate in patients with hemophilia a and inhibitors Progress in Clinical and Biological Research 324: 59-68
Landolfi, R.; de Cristofaro, R.; Lazzareschi, I.; Riccardi, R.; Mariani, G. 2000: Immune tolerance by intermittent factor VIIi boluses in two high responder hemophilia a patients Haematologica 85(10 Suppl): 73-74
Scharf, R.; Kucharski, W.; Lopaciuk, S.; Celińska, W.; Dmytrow, A.; Domański, K.; Gonet, S.; Miastkowski, Z.; Nowakowska, I.; Przybylski, A. 1991: Preliminary experience with achieving immune tolerance in patients with hemophilia a and circulating factor VIIi inhibitor Acta Haematologica Polonica 22(1): 92-99
Kessler, C.M.; Ludlam, C.A. 1993: The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group Seminars in Hematology 30(2 Suppl. 1): 22-27
Moss, A.; Fryer, J.P.; Leventhal, J.R.; Simone, P.; Chen, S.; Reinsmoen, N.; Matas, A.J. 1994: Analysis of the human anti-pig cellular immune response using the Hu-scid mouse-porcine skin graft model Transplantation Proceedings 26(3): 1209
Ambriz-Fernández, R.; Reyna-Fregoso, M.P.; Pizzuto-Chávez, J.; Rodríguez-Moyado, H.; Farfán-Canto, J.M.; Trueba-Christy, E.; Collazo-Jaloma, J. 1985: Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. a study of the cooperative group of hemophilia Archivos de Investigacion Medica 16(3): 225-235
Ill, C.R.; Yang, C.Q.; Bidlingmaier, S.M.; Gonzales, J.N.; Burns, D.S.; Bartholomew, R.M.; Scuderi, P. 1997: Optimization of the human factor VIII complementary DNA expression plasmid for gene therapy of hemophilia A Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 8 Suppl. 2: S23-S30
Fijnvandraat, K.; Berntorp, E.; ten Cate, J.W.; Johnsson, H.; Peters, M.; Savidge, G.; Tengborn, L.; Spira, J.; Stahl, C. 1997: Recombinant, B-domain deleted factor VIII (r-VIII SQ): pharmacokinetics and initial safety aspects in hemophilia A patients Thrombosis and Haemostasis 77(2): 298-302
Vianello, F.; Tison, T.; Tagariello, G.; Zerbinati, P.; Zanon, E.; Scarano, L.; Girolami, A. 1999: Serological markers of autoimmunity in patients with hemophilia A: the role of hepatitis C virus infection, alpha-interferon and factor VIII treatment in skewing the immune system toward autoreactivity Blood Coagulation and Fibrinolysis: An International Journal in Haemostasis and Thrombosis 10(6): 393-397
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Antonarakis, S.E.; Kazazian, H.H. 1990: The molecular basis of hemophilia A (factor VIII deficiency) in man; progress report from the Johns Hopkins University Hemophilia Project Progress in Clinical and Biological Research 324: 1-11
Allersma, D.P.; Smid, W.M.; van der Does, J.A.; van der Meer, J.; Briët, E. 1996: Effects of chronic factor VIII substitution on immune parameters in HIV seronegative haemophiliacs: a comparison between cryoprecipitate and factor VIII concentrate Thrombosis and Haemostasis 75(2): 261-266
DiMichele, D.; Kroner, B. 2000: The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: the North American Registry. Factor VIII/IX Subcommittee of the International Society for Thrombosis and Hemostasis Haematologica 85(10 Suppl): 40
Walker, I.; Poon, M.C. 1992: Recombinant factor VIII concentrate. The MSAC, Canadian Hemophilia Society. Canadian Hemophilia Clinic Directors Group Lancet 339(8784): 61-62
Mahasandana, C.; Patharathienskul, D.; Suvatte, V. 1993: Hemophilia with factor VIII and factor IX inhibitors, incidence, bleeding problems and management Southeast Asian Journal of Tropical Medicine and Public Health 24(Suppl 1): 106-112
Mahasandana, C.; Suvatte, V.; Püng-amritt, P.; Tuchinda, S. 1979: Von Willebrand's disease: studies of platelet functions, factor VIII procoagulant activity (F VIII C) and factor VIII-related antigen (F VIII RAg) in three families Southeast Asian Journal of Tropical Medicine and Public Health 10(2): 243-247
Teitel, J.M.; Lau, H.K.; Garvey, M.B. 2002: Discrepancies in measured factor VIIi activity in patients treated with factor VIIi concentrate of human or porcine origin Thrombosis and Haemostasis 88(1): 159-160
Lane, J.L.; Ekert, H.; Vafiadis, A. 1979: Affinity chromatography of human factor VIII using human and rabbit antibodies to Factor VIII Thrombosis and Haemostasis 42(4): 1306-1315